X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TD-0148A is a second-generation lysergic acid diethylamide ("LSD") derivative that BetterLife believes will mimic the therapeutic potential of LSD without producing hallucinogenic effects or other psychoactive side-effects.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: TD-0148A
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: BetterLife Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 24, 2021
Details:
MatriSys plans to quickly advance the development of MSB-3163 and conduct a first-in-human proof-of-concept clinical trial. MSB3163 exhibited potency greater than antibiotics commonly used in the treatment of acne in clinical trails.
Lead Product(s): MSB-3163
Therapeutic Area: Dermatology Product Name: MSB-3163
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: MatriSys Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 18, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
